Cardiac Events Linked to Macrolide Antibiotics
By HospiMedica International staff writers Posted on 29 Nov 2015 |
Macrolide antibiotic use is associated with an increased risk of sudden cardiac death (SCD) and ventricular tachyarrhythmia (VTA), according to a new study.
Researchers at the First Affiliated Hospital of Sun Yat-Sen University (SYSU; Guangzhou, China) conducted a meta-analysis of studies to examine the link between use of oral macrolide antibiotics and risk of SCD, VTA, cardiovascular death, and death from any cause. The researchers performed a search of published reports by using MEDLINE and EMBASE with no restrictions. In all, 33 studies involving 20,779,963 participants met study criteria.
The results showed that patients taking macrolides experienced a 2.5 fold risk of developing SCD or VTA, and a 31% increased risk of cardiovascular death; no association was found between macrolides use and all-cause death or any cardiovascular events. The relative risk (RR) associated with SCD or VTA was 3.40 for azithromycin, 2.16 for clarithromycin, and 3.61 for erythromycin, respectively. The RR for cardiovascular death was 1.54 for azithromycin and 1.48 for clarithromycin; no association was noted between roxithromycin and adverse cardiac outcomes. The study was published in the November 2015 issue of the Journal of the American College of Cardiology (JACC).
“Although currently it is still too early to conclude that the observed high-risk is due to drug effect, related to the type of infectious disease, or underlying comorbidities,” said study coauthor Chia-Hsuin Chang, MD. “It is suggested that physicians should pay more attention to their potential cardiac toxicity, avoid unnecessary use of macrolides, and shift to betalactam antibiotics if possible.”
Macrolides are protein synthesis inhibitors whose activity stems from the presence of a macrolide ring. They are used to treat infections caused by Gram-positive and limited Gram-negative bacteria, and some respiratory tract and soft-tissue infections. Since the antimicrobial spectrum of macrolides is slightly wider than that of penicillin, they are therefore a common substitute in patients with a penicillin allergy.
Related Links:
Sun Yat-Sen University
Researchers at the First Affiliated Hospital of Sun Yat-Sen University (SYSU; Guangzhou, China) conducted a meta-analysis of studies to examine the link between use of oral macrolide antibiotics and risk of SCD, VTA, cardiovascular death, and death from any cause. The researchers performed a search of published reports by using MEDLINE and EMBASE with no restrictions. In all, 33 studies involving 20,779,963 participants met study criteria.
The results showed that patients taking macrolides experienced a 2.5 fold risk of developing SCD or VTA, and a 31% increased risk of cardiovascular death; no association was found between macrolides use and all-cause death or any cardiovascular events. The relative risk (RR) associated with SCD or VTA was 3.40 for azithromycin, 2.16 for clarithromycin, and 3.61 for erythromycin, respectively. The RR for cardiovascular death was 1.54 for azithromycin and 1.48 for clarithromycin; no association was noted between roxithromycin and adverse cardiac outcomes. The study was published in the November 2015 issue of the Journal of the American College of Cardiology (JACC).
“Although currently it is still too early to conclude that the observed high-risk is due to drug effect, related to the type of infectious disease, or underlying comorbidities,” said study coauthor Chia-Hsuin Chang, MD. “It is suggested that physicians should pay more attention to their potential cardiac toxicity, avoid unnecessary use of macrolides, and shift to betalactam antibiotics if possible.”
Macrolides are protein synthesis inhibitors whose activity stems from the presence of a macrolide ring. They are used to treat infections caused by Gram-positive and limited Gram-negative bacteria, and some respiratory tract and soft-tissue infections. Since the antimicrobial spectrum of macrolides is slightly wider than that of penicillin, they are therefore a common substitute in patients with a penicillin allergy.
Related Links:
Sun Yat-Sen University
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure